Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis

Launched by BENHA UNIVERSITY · Nov 8, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called mirabegron, which is being tested to see if it can help treat primary nocturnal enuresis, commonly known as bedwetting. The goal is to compare the effectiveness and safety of mirabegron with another medication called desmopressin and also with behavioral therapy, which involves strategies to help manage bedwetting. The trial is currently recruiting participants aged 18 to 26 and 54 to 78, regardless of gender.

To be eligible for the study, participants must have primary nocturnal enuresis, meaning they wet the bed without a known medical cause, and they should not experience daytime wetting. They need to have wet the bed at least four times in the last month and should have normal medical examinations. If you or someone you know is interested in participating, they can expect to receive either the mirabegron medication, desmopressin, or behavioral therapy during the study. This trial aims to find effective treatments for bedwetting, which can be an important issue for many individuals and families.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • primary nocturnal enuresis,
• • negligible daytime wetting,
• • wet at least 4 times over 4 weeks
• • normal clinical examination with no neurological or urological cause for the enuresis
• Exclusion Criteria:
• • secondary enuresis, polysymptomatic
• • neurologic bladder, neurological disorders,
• • urinary incontinence disorders
• • previous anti NE drugs.